Aspen's Attractiveness To Investors Increases

BMI View: The investor preference for developed market equities over emerging market equities has negatively impacted Aspen Pharmaceuticals's share price. Although the price may have been overinflated by the reverse trend, BMI believes the company is fundamentally strong.

To read the full article, please choose one of the following options: